Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma

Thorax

Volumn 63, Issue 9, 2008, Pages 784-790

  Bhavsar, P ^a   Hew, M ^a   Khorasani, N ^a   Torrego, A ^a   Barnes, P J ^a   Adcock, I ^a   Chung, K F ^a,b  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BRONCHODILATING AGENT; CELL EXTRACT; CORTICOSTEROID; CYTOKINE; DEXAMETHASONE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; PREDNISOLONE; RNA;

ADULT; ARTICLE; ASTHMA; ATOPY; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID INSENSITIVITY; DISEASE DURATION; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; EOSINOPHIL; FEMALE; FIBEROPTIC BRONCHOSCOPY; FORCED EXPIRATORY VOLUME; GENE EXPRESSION; HUMAN; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; LYMPHOCYTE; MALE; NEUTROPHIL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERNATANT; TREATMENT RESPONSE;

EID: 51249109929     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2007.090027     Document Type: Article

References (36)

1. Stirling RG, Chung KF. Severe asthma: definition and mechanisms. Allergy 2001;55:1-16.
2. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170:836-44.
3. Dolan CM, Fraher KE, Bleecker ER, et al. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004;92:32-9.
4. Godard P, Chanez P, Siraudin L, et al. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002;19:61-7.
5. Chung KF, Godard P, Adelroth E, et al. Difficult/therapy- resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society. Eur Respir J 1999;13:1198-208.
6. American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000;162:2341-51.
7. Robinson DS, Campbell DA, Durham SR, et al. Systematic assessment of difficult-to-treat asthma. Eur Respir J 2003;22:478-83.
8. European Network for Understanding Mechanisms of Severe Asthma. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003;22:470-7.
9. Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007;119:405-13.
10. Woolcock AJ. Corticosteroid-resistant asthma. Definitions. Am J Respir Crit Care Med 1996;154(2 Pt 2):S45-8.
11. Corrigan J, Brown PH, Barnes NC, et al. Glucocorticoid resistance in chronic asthma. Am Rev Respir Dis 1991;144:1016-25.
12. Wilkinson JRW, Crea AEG, Clark TJH, et al. Identification and characterization of a monocyte-derived neutrophil-activating factor in corticosteroid-resistant bronchial asthma. J Clin Invest 1989;84:1930-41.
13. Viksman MY, Liu MC, Bickel CA, et al. Phenotypic analysis of alveolar macrophages and monocytes in allergic airway inflammation. I. Evidence for activation of alveolar macrophages, but not peripheral blood monocytes, in subjects with allergic rhinitis and asthma. Am J Respir Crit Care Med 1997;155:858-63.
14. John M, Lim S, Seybold J, et al. Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1a, granulocyte-macrophage colony-stimulating factor and interferon-Y release from alveolar macrophages in asthma. Am J Respir Crit Care Med 1998;157:256-62.
15. Cluzel M, Damon M, Chanez P, et al. Enhanced alveolar cell luminol-dependent chemiluminescence in asthma. J Allergy Clin Immunol 1987;80:195-201.
16. Hew M, Bhavsar P, Torrego A, et al. Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. Am J Respir Crit Care Med 2006;174:134-41.
17. Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003;2:717-26.
18. Koch A, Giembycz M, Ito K, et al. Mitogen-activated protein kinase modulation of nuclear factor-kappaB-induced granulocyte macrophage-colony-stimulating factor release from human alveolar macrophages. Am J Respir Cell Mol Biol 2004;30:342-9.
19. Koch A, Giembycz M, Stirling RG, et al. Effect of smoking on MAP kinase-induced modulation of IL-8 in human alveolar macrophages. Eur Respir J 2004;23:805-12.
20. Irusen E, Matthews JG, Takahashi A, et al. p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 2002;109:649-57.
21. Lasa M, Abraham SM, Boucheron C, et al. Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol 2002;22:7802-11.
22. Kassel O, Sancono A, Kratzschmar J, et al. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J 2001;20:7108-16.
23. Chen P, Li J, Barnes J, et al. Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. J Immunol 2002;169: 6408-16.
24. Zhao Q, Shepherd EG, Manson ME, et al. The role of mitogen-activated protein kinase phosphatase-1 in the response of alveolar macrophages to lipopolysaccharide: attenuation of proinflammatory cytokine biosynthesis via feedback control of p38. J Biol Chem 2005;280:8101-8.
25. Abraham SM, Clark AR. Dual-specificity phosphatase 1: a critical regulator of innate immune responses. Biochem Soc Trans 2006;34:1018-23.
26. Clark AR. MAP kinase phosphatase 1: a novel mediator of biological effects of glucocorticoids? J Endocrinol 2003;178:5-12.
27. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160:1001-8.
28. Jatakanon A, Uasuf C, Maziak W, et al. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999;160:1532-9.
29. Nguyen LT, Lim S, Oates T, et al. Oral but not inhaled corticosteroid therapy increases airway neutrophils in asthma. Respir Med 2005;99:200-7.
30. Szatmary Z, Garabedian MJ, Vilcek J. Inhibition of glucocorticoid receptor-mediated transcriptional activation by p38 mitogen-activated protein (MAP) kinase. J Biol Chem 2004;279:43708-15.
31. Saccani S, Pantano S, Natoli G. p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat Immunol 2002;3:69-75.
32. Cosio BG, Mann B, Ito K, et al. Histone acetylase and deacetylase activity in alveolar macrophages and blood mononocytes in asthma. Am J Respir Crit Care Med 2004;170:141-7.
33. Dean JL, Sully G, Clark AR, et al. The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation. Cell Signal 2004;16:1113-21.
34. Sirenko OI, Lofquist AK, DeMaria CT, et al. Adhesion-dependent regulation of an A+U-rich element-binding activity associated with AUF1. Mol Cell Biol 1997;17:3898-906.
35. Wang SW, Pawlowski J, Wathen ST, et al. Cytokine mRNA decay is accelerated by an inhibitor of p38-mitogen-activated protein kinase. Inflamm Res 1999;48:533-8.
36. Tebo J, Der S, Frevel M, et al. Heterogeneity in control of mRNA stability by AU-rich elements. J Biol Chem 2003;278:12085- 93.